2018 International Congress

Saturday, October 6, 2018

1:45pm-3:15pm

Quantitative assessment of the effectiveness of adaptive Deep Brain Stimulation in Parkinson’s disease

D. Piña-Fuentes, M. Tijssen, M. Oterdoom, S. Little, J. van Zijl, T. van Laar, P. Brown, M. van Dijk, M. Beudel (Groningen, Netherlands)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Quantitative EEG and medial temporal lobe atrophy in early Parkinson’s disease with behavioral and psychological symptoms

J.Y. Ahn, H.T. Kim (Seoul, Republic of Korea)

Cognitive Disorders  ·  Hall 3FG

1:45pm-3:15pm

Quantitative oculomotor assessment and non-motor biomarkers in late-onset GM2 gangliosidosis

C. Stephen, D. Balkwill, P. James, K. Sassower, J. Schmahmann, R. Lewis, F. Eichler (Boston, MA, USA)

Rare Genetic and Metabolic Diseases  ·  Hall 3FG

1:45pm-3:15pm

Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study

K. Chaudhuri, D. Weintraub, A. Antonini, W. Robieson, M. Li, K. Chatamra, J. Benesh, M. Facheris (London, United Kingdom)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Real-World Outcomes Using a Novel Directional Lead from a Deep Brain Stimulation (DBS) Registry for Parkinson’s Disease

G. Deuschl, R. Jain, H. Scholtes, A. Wang, M. Barbe, A. Kühn, M. Pötter-Nerger, J. Volkmann, S. Paschen, J. Vesper (Kiel, Germany)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Reduction of neuroinflammation by selective inhibition of the N-type calcium channel is beneficial in various animal models of neurodegeneration, here in the SOD1G93A transgenic mouse model of ALS

J. Post-Schulz, A. Willuweit, V. Kogel, K. Langen, J. Kutzsche, D. Willbold (Jülich, Germany)

Pathophysiology (Other Movement Disorders)  ·  Hall 3FG

1:45pm-3:15pm

Relationship between Age-related Frailty and Intra-individual Variability of Reaction Time in Healthy Seniors: Implications for Parkinson’s disease

L. Lu (Guangzhou, People’s Republic of China)

Cognitive Disorders  ·  Hall 3FG

1:45pm-3:15pm

Relationship between CTG repeats, Muscle Weakness and Respiratory Dysfunction in Myotonic Dystrophy Type 1

A. Hawkins, K. Abdul Razak, T. Khoo, K. Tran, R. Jackson (Meadowbrook, Australia)

Pathophysiology (Other Movement Disorders)  ·  Hall 3FG

1:45pm-3:15pm

Relationship between non-motor symptom symptoms and clinical symptoms in Parkinson’s disease using “Non-Motor Symptom assessment scale for Parkinson’s disease”

T. Matsubara, K. Suzuki, H. Fujita, M. Matsubara, A. Numao, H. Sakuramoto, Y. Watanabe, T. Kadowaki, K. Hirata (Tochigi, Japan)

Clinical Trials and Therapy in Movement Disorders  ·  Hall 3FG

1:45pm-3:15pm

Relationship between Patient Global Impression of Change and other Efficacy Endpoints in Parkinson’s Disease: A post-hoc analysis from combined BIPARK-I and II

J. Ferreira, W. Poewe, O. Rascol, R. Costa, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG